314 related articles for article (PubMed ID: 21725372)
41. Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor.
Farina L; Spina F; Guidetti A; Longoni P; Ravagnani F; Dodero A; Montefusco V; Carlo-Stella C; Corradini P
Leuk Lymphoma; 2014 Feb; 55(2):331-6. PubMed ID: 23656194
[TBL] [Abstract][Full Text] [Related]
42. Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.
Chaudhary L; Awan F; Cumpston A; Leadmon S; Watkins K; Tse W; Craig M; Hamadani M
J Clin Apher; 2013 Oct; 28(5):359-67. PubMed ID: 23765597
[TBL] [Abstract][Full Text] [Related]
43. Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization.
Costa LJ; Miller AN; Alexander ET; Hogan KR; Shabbir M; Schaub C; Stuart RK
Bone Marrow Transplant; 2011 Apr; 46(4):523-8. PubMed ID: 20622909
[TBL] [Abstract][Full Text] [Related]
44. Addition of plerixafor for CD34+ cell mobilization in six healthy stem cell donors ensured satisfactory grafts for transplantation.
Hauge AW; Haastrup EK; Sengeløv H; Minulescu L; Dickmeiss E; Fischer-Nielsen A
Transfusion; 2014 Apr; 54(4):1055-8. PubMed ID: 23944772
[TBL] [Abstract][Full Text] [Related]
45. Efficacy of just-in-time plerixafor rescue for Hodgkin's lymphoma patients with poor peripheral blood stem cell mobilization.
Yuan S; Nademanee A; Kaniewski M; Palmer J; Shayani S; Wang S
Transfusion; 2014 Aug; 54(8):2015-21. PubMed ID: 24660786
[TBL] [Abstract][Full Text] [Related]
46. Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.
Lor KW; Helmons PJ; Belew H; Lane JR; Ball ED
Pharmacotherapy; 2012 Jul; 32(7):596-603. PubMed ID: 22760691
[TBL] [Abstract][Full Text] [Related]
47. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF.
D'Addio A; Curti A; Worel N; Douglas K; Motta MR; Rizzi S; Dan E; Taioli S; Giudice V; Agis H; Kopetzky G; Soutar R; Casadei B; Baccarani M; Lemoli RM
Bone Marrow Transplant; 2011 Mar; 46(3):356-63. PubMed ID: 20577218
[TBL] [Abstract][Full Text] [Related]
48. A plerixafor-based strategy allows adequate hematopoietic stem cell collection in poor mobilizers: results from the Canadian Special Access Program.
Sheppard D; Bredeson C; Huebsch L; Allan D; Tay J
Bone Marrow Transplant; 2014 Jun; 49(6):751-5. PubMed ID: 24614838
[TBL] [Abstract][Full Text] [Related]
49. Plerixafor in poor stem cell mobilizers: the Belgian Compassionate Use Program.
Selleslag D; Dierickx D; Breems DA; Huynh P; Van De Velde A; Meers S; Brouwer E; Mertens A
Acta Clin Belg; 2011; 66(3):200-4. PubMed ID: 21837928
[TBL] [Abstract][Full Text] [Related]
50. Optimizing mobilization strategies in difficult-to-mobilize patients: The role of plerixafor.
Goker H; Etgul S; Buyukasik Y
Transfus Apher Sci; 2015 Aug; 53(1):23-9. PubMed ID: 26099666
[TBL] [Abstract][Full Text] [Related]
51. CD34+ cell subclasses and lymphocyte subsets in blood grafts collected after various mobilization methods in myeloma patients.
Varmavuo V; Mäntymaa P; Silvennoinen R; Nousiainen T; Kuittinen T; Jantunen E
Transfusion; 2013 May; 53(5):1024-32. PubMed ID: 22897584
[TBL] [Abstract][Full Text] [Related]
52. Systematic review of randomized controlled trials of hematopoietic stem cell mobilization strategies for autologous transplantation for hematologic malignancies.
Sheppard D; Bredeson C; Allan D; Tay J
Biol Blood Marrow Transplant; 2012 Aug; 18(8):1191-203. PubMed ID: 22261379
[TBL] [Abstract][Full Text] [Related]
53. Mobilization of healthy donors with plerixafor affects the cellular composition of T-cell receptor (TCR)-αβ/CD19-depleted haploidentical stem cell grafts.
Rutella S; Filippini P; Bertaina V; Li Pira G; Altomare L; Ceccarelli S; Brescia LP; Lucarelli B; Girolami E; Conflitti G; Cefalo MG; Bertaina A; Corsetti T; Moretta L; Locatelli F
J Transl Med; 2014 Sep; 12():240. PubMed ID: 25179788
[TBL] [Abstract][Full Text] [Related]
54. Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin's lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony-stimulating factor.
Varmavuo V; Mäntymaa P; Kuittinen T; Nousiainen T; Jantunen E
Transfusion; 2012 Aug; 52(8):1785-91. PubMed ID: 22304442
[TBL] [Abstract][Full Text] [Related]
55. Plerixafor added to G-CSF allows mobilization of a sufficient number of hematopoietic progenitors without impacting the efficacy of TCR-alpha/beta depletion in pediatric haploidentical and genoidentical donors failing to mobilize with G-CSF alone.
Kurnikova E; Trakhtman P; Pershin D; Ilyushina M; Khismatullina R; Maschan M; Novichkova G; Maschan A
J Clin Apher; 2021 Aug; 36(4):547-552. PubMed ID: 33682959
[TBL] [Abstract][Full Text] [Related]
56. Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: a phase I clinical trial.
Herbert KE; Demosthenous L; Wiesner G; Link E; Westerman DA; Came N; Ritchie DS; Harrison S; Seymour JF; Prince HM
Bone Marrow Transplant; 2014 Aug; 49(8):1056-62. PubMed ID: 24887382
[TBL] [Abstract][Full Text] [Related]
57. Characterization of hematopoietic stem cell subsets from patients with multiple myeloma after mobilization with plerixafor.
Taubert I; Saffrich R; Zepeda-Moreno A; Hellwig I; Eckstein V; Bruckner T; Ho AD; Wuchter P
Cytotherapy; 2011 Apr; 13(4):459-66. PubMed ID: 21077729
[TBL] [Abstract][Full Text] [Related]
58. Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure.
Worel N; Fritsch G; Agis H; Böhm A; Engelich G; Leitner GC; Geissler K; Gleixner K; Kalhs P; Buxhofer-Ausch V; Keil F; Kopetzky G; Mayr V; Rabitsch W; Reisner R; Rosskopf K; Ruckser R; Zoghlami C; Zojer N; Greinix HT
J Clin Apher; 2017 Aug; 32(4):224-234. PubMed ID: 27578390
[TBL] [Abstract][Full Text] [Related]
59. Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience.
Fowler CJ; Dunn A; Hayes-Lattin B; Hansen K; Hansen L; Lanier K; Nelson V; Kovacsovics T; Leis J; Calandra G; Maziarz RT
Bone Marrow Transplant; 2009 Jun; 43(12):909-17. PubMed ID: 19182831
[TBL] [Abstract][Full Text] [Related]
60. Plerixafor on demand in ten healthy family donors as a rescue strategy to achieve an adequate graft for stem cell transplantation.
Gattillo S; Marktel S; Rizzo L; Malato S; Malabarba L; Coppola M; Assanelli A; Milani R; De Freitas T; Corti C; Bellio L; Ciceri F
Transfusion; 2015 Aug; 55(8):1993-2000. PubMed ID: 25721167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
